Real-World Evaluation of Clinical Response and Long-Term Healthcare Resource Utilization Patterns Following Treatment with a Digital Therapeutic for Chronic Insomnia.

CBT-I SHUTi Somryst chronic insomnia cognitive behavioral therapy for insomnia prescription digital therapeutic

Journal

ClinicoEconomics and outcomes research : CEOR
ISSN: 1178-6981
Titre abrégé: Clinicoecon Outcomes Res
Pays: New Zealand
ID NLM: 101560564

Informations de publication

Date de publication:
2022
Historique:
received: 07 04 2022
accepted: 01 07 2022
entrez: 19 8 2022
pubmed: 20 8 2022
medline: 20 8 2022
Statut: epublish

Résumé

This analysis evaluated insomnia severity and long-term impact on healthcare resource utilization (HCRU) and costs after treatment with Somryst Change from baseline in insomnia severity index (ISI) score was assessed using last observed ISI score. A pre/post analysis of claims data was conducted, comparing HCRU in patients with self-identified sleep problems who successfully initiated the therapeutic (index date) between June 1, 2016 and December 31, 2018. A total of 248 patients were analyzed (median age 56.5 years, 57.3% female, mean ISI score 19.13, 52.4% treated with sleep aid medications pre-index). After 9 weeks, mean ISI score declined by 37.2% from baseline (19.1 vs 12.0), 58.8% of patients achieved ISI responder status (ISI score improved by =>7; NNT: 1.7), and 26.6% of patients achieved insomnia remission (ISI score <8; NNT for remission: 3.8). After two-year follow-up, post-index events were reduced (compared to 2 years pre-index) for emergency department visits (-53%; IRR: 0.47; 95% CI 0.27, 0.82; In a real-world cohort of patients with chronic insomnia, treatment with a digital therapeutic delivering CBT-I was associated with reductions in insomnia severity, emergency department visits, and net costs.

Sections du résumé

Background and Objectives UNASSIGNED
This analysis evaluated insomnia severity and long-term impact on healthcare resource utilization (HCRU) and costs after treatment with Somryst
Methods UNASSIGNED
Change from baseline in insomnia severity index (ISI) score was assessed using last observed ISI score. A pre/post analysis of claims data was conducted, comparing HCRU in patients with self-identified sleep problems who successfully initiated the therapeutic (index date) between June 1, 2016 and December 31, 2018.
Results UNASSIGNED
A total of 248 patients were analyzed (median age 56.5 years, 57.3% female, mean ISI score 19.13, 52.4% treated with sleep aid medications pre-index). After 9 weeks, mean ISI score declined by 37.2% from baseline (19.1 vs 12.0), 58.8% of patients achieved ISI responder status (ISI score improved by =>7; NNT: 1.7), and 26.6% of patients achieved insomnia remission (ISI score <8; NNT for remission: 3.8). After two-year follow-up, post-index events were reduced (compared to 2 years pre-index) for emergency department visits (-53%; IRR: 0.47; 95% CI 0.27, 0.82;
Conclusion UNASSIGNED
In a real-world cohort of patients with chronic insomnia, treatment with a digital therapeutic delivering CBT-I was associated with reductions in insomnia severity, emergency department visits, and net costs.

Identifiants

pubmed: 35983014
doi: 10.2147/CEOR.S368780
pii: 368780
pmc: PMC9379126
doi:

Types de publication

Journal Article

Langues

eng

Pagination

537-546

Informations de copyright

© 2022 Forma et al.

Déclaration de conflit d'intérêts

FF, FPT, XX, FFV, and YAM are employees of Pear Therapeutics (US), Inc. FPT also reports equity and employment from BeHealth Solutions, during the conduct of the study; and was a previous faculty member at institution (University of Virginia) that developed precursor (SHUTi) to this work. TGK and RB are employees of Market Access Consulting, Labcorp Drug Development, which participated in this study under contract with Pear Therapeutics (US), Inc. DCM is a consultant of Strategic Therapeutics, LLC, which participated in this study under contract with Pear Therapeutics (US), Inc. The authors report no other conflicts of interest in this work.

Références

Expert Rev Med Devices. 2020 Dec;17(12):1239-1248
pubmed: 33226269
Curr Med Res Opin. 2005 Nov;21(11):1785-92
pubmed: 16307699
Community Ment Health J. 2021 Oct;57(7):1244-1251
pubmed: 34165695
Psychooncology. 2012 Jul;21(7):695-705
pubmed: 21538678
E J Appl Psychol. 2008;4(2):32-42
pubmed: 20953264
Behav Sleep Med. 2013;11(1):40-55
pubmed: 23347116
Sleep Med. 2021 Jan;77:348-354
pubmed: 32593614
Ann Intern Med. 2016 Jul 19;165(2):125-33
pubmed: 27136449
J Natl Cancer Inst. 2018 Aug 1;110(8):880-887
pubmed: 29471478
J Clin Sleep Med. 2007 Aug 15;3(5 Suppl):S7-10
pubmed: 17824495
Sleep. 2012 Feb 01;35(2):287-302
pubmed: 22294820
Sleep. 2009 Aug;32(8):1027-37
pubmed: 19725254
Behav Res Ther. 2022 Jun;153:104084
pubmed: 35405424
BMJ. 2019 May 10;365:l2165
pubmed: 31076387
Sleep Med Rev. 2007 Jun;11(3):163-78
pubmed: 17442599
Sleep Med Rev. 2016 Dec;30:1-10
pubmed: 26615572
J Am Geriatr Soc. 2015 Nov;63(11):2227-46
pubmed: 26446832
J Psychopharmacol. 2019 Aug;33(8):923-947
pubmed: 31271339
J Neuroinflammation. 2020 Oct 6;17(1):289
pubmed: 33023629
Prog Cardiovasc Dis. 2009 Jan-Feb;51(4):294-302
pubmed: 19110131
Ann Behav Med. 2021 Jun 2;55(6):592-599
pubmed: 33057694
Behav Sleep Med. 2020 Sep-Oct;18(5):680-689
pubmed: 31470745
J Gen Intern Med. 2018 Jun;33(6):955-962
pubmed: 29619651
J Clin Psychol. 2010 Nov;66(11):1148-60
pubmed: 20853442
Lancet Psychiatry. 2016 Apr;3(4):333-41
pubmed: 26827250
PLoS One. 2015 Oct 01;10(10):e0137117
pubmed: 26426805
Behav Sleep Med. 2009;7(4):210-22
pubmed: 19787491
J Clin Sleep Med. 2008 Oct 15;4(5):487-504
pubmed: 18853708
Behav Sleep Med. 2016 Nov-Dec;14(6):687-98
pubmed: 27159249
Sleep. 2007 Feb;30(2):213-8
pubmed: 17326547
Chest. 2014 Nov;146(5):1387-1394
pubmed: 25367475
J Sleep Res. 2017 Dec;26(6):675-700
pubmed: 28875581
Sleep Med Rev. 2017 Feb;31:58-69
pubmed: 27090821
J Affect Disord. 2011 Dec;135(1-3):10-9
pubmed: 21300408
JAMA Psychiatry. 2017 Jan 01;74(1):68-75
pubmed: 27902836
Can J Public Health. 2020 Oct;111(5):654-657
pubmed: 32700231
Sleep Med. 2017 Aug;36 Suppl 1:S43-S47
pubmed: 28648226
J Clin Sleep Med. 2017 Feb 15;13(2):307-349
pubmed: 27998379
Sleep. 2019 Apr 1;42(4):
pubmed: 30649500
J Clin Sleep Med. 2017 Jan 15;13(1):127-135
pubmed: 27998380

Auteurs

Felicia Forma (F)

Pear Therapeutics, Inc., Medical Affairs Department, Boston, MA, USA.

Tyler G Knight (TG)

Labcorp Drug Development, Market Access Consulting Department, Gaithersburg, MD, USA.

Frances P Thorndike (FP)

Pear Therapeutics, Inc., Medical Affairs Department, Boston, MA, USA.

Xiaorui Xiong (X)

Pear Therapeutics, Inc., Medical Affairs Department, Boston, MA, USA.

Rebecca Baik (R)

Labcorp Drug Development, Market Access Consulting Department, Gaithersburg, MD, USA.

Fulton F Velez (FF)

Pear Therapeutics, Inc., Medical Affairs Department, Boston, MA, USA.

Yuri A Maricich (YA)

Pear Therapeutics, Inc., Medical Affairs Department, Boston, MA, USA.

Daniel C Malone (DC)

Strategic Therapeutics, LLC, Oro Valley, AZ, USA.

Classifications MeSH